Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2025-01-23 Earnings Release
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated January 23, 2025, announcing the financial results of Mankind Pharma for the third quarter and nine months ended December 31, 2024 (Q3FY25 and 9M FY25). It contains detailed financial performance data including revenue, EBITDA, PAT, segmental revenue, and EPS figures. The document also includes management commentary on business performance and outlook, as well as information about an upcoming earnings conference call scheduled for January 24, 2025. The presence of comprehensive quarterly financial data and management discussion indicates this is a quarterly earnings release. The document is not a full interim report with extensive financial statements but rather a press release summarizing key financial results and business highlights for the quarter. Therefore, the appropriate classification is Earnings Release (ER). The document length (11,329 characters) and content confirm it is not merely an announcement of a report but the actual earnings release itself. Q3 2025
2025-01-23 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings
2025-01-23 English
Outcome of Board Meeting
Regulatory Filings
2025-01-23 English
Financial Result Updates
Regulatory Filings
2025-01-23 English
General Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about an order received from a tax authority (Additional Commissioner, CGST) regarding a penalty under the CGST Act. The document states the company's view on the order and its intention to appeal. It explicitly mentions that there is no material impact on financials or operations. The document is a regulatory announcement about a legal/tax matter and does not contain financial statements or detailed financial analysis. It is not a full audit report, annual report, or earnings release. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure under SEBI regulations.
2025-01-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 60% confidence The document is an announcement dated January 14, 2025, informing about an upcoming investor conference call scheduled for January 24, 2025, to discuss Q3 & 9M FY25 business performance and results. It includes details for joining the call and lists senior management participants. There are no actual financial statements or detailed financial analysis included in the text. The document serves as an invitation or notice for the earnings call rather than the transcript or report of the call itself. Therefore, it is best classified as a Call Transcript (CT) only if it contained the full transcript, but since this is an invitation notice, it does not qualify as a transcript. It is also not a report publication announcement or regulatory filing because it is specifically about the call. Given the options, the closest and most appropriate classification is Call Transcript (CT) because the document is about the earnings call event, but since it is only an invitation, the confidence is moderate.
2025-01-14 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.